Ad hoc announcement pursuant to Art. 53 LR
Zurich, 24 September 2026

Xlife Sciences reports an eventful first half of 2026 marked by strategic milestones and portfolio progress

Zurich, 24 September 2026: Xlife Sciences AG (SIX: XLS, «Xlife Sciences») looks back on a first half of 2026 marked by significant capital markets progress, operational developments across the portfolio and the continued expansion of its platform. A major milestone was the listing of portfolio company VERAXA Biotech AG (NASDAQ: VRXA, «VERAXA Biotech») on the NASDAQ Capital Market. At the same time, numerous strategic and scientific advances were achieved across the portfolio.

VERAXA Biotech: Focus now shifts to operational development and partnerships
With the completion of the business combination and the commencement of trading on NASDAQ in June 2026, VERAXA Biotech reached an important milestone in its corporate development. Following the listing, the focus now shifts to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and their products. The secured financing base provides the foundation for the next development steps and for advancing VERAXA Biotech's valuation. For Xlife Sciences, VERAXA remains an important building block in the development of selected portfolio companies and their innovations.

Operational progress across the portfolio
In addition to its capital markets activities, several portfolio companies achieved important operational and scientific milestones.

- x-kidney diagnostics: Strategic partner Quant Biomarkers received approximately CHF 1 million in non-dilutive innovation funding to further develop a biomarker platform for the early detection of chronic kidney disease.

- saniva diagnostics: The company successfully completed the second clinical study of its NeuroMex system for the early detection of neurodegenerative diseases. The focus now is on establishing partnerships with international medical technology companies.

- Axenoll: Together with an industrial partner, the company is establishing the prerequisites for pre-series production of biomaterial-based applications and advancing preparations for a subsequent market launch.

- FUSE-AI: Successful recertification under ISO 13485 strengthens the company's positioning in AI-based medical software solutions.

- inflamed pharma: The company made further progress with its proprietary formulation technology and is expanding its portfolio of innovative active ingredients for applications in health, nutrition and healthy aging.

Strong patent portfolio as the basis for future value creation
The portfolio's innovative strength continues to be protected by an extensive patent portfolio. In the first half of 2026, four additional patents were granted in key international markets. Overall, the portfolio comprises 416 patents and patent applications, including 216 granted intellectual property rights. New patent grants for Axenoll, alytas therapeutics and saniva diagnostics in key markets strengthen the technological and commercial position of these portfolio companies and provide a foundation for future licensing and partnership models.

Oliver R. Baumann, CEO of Xlife Sciences, comments:
«*The first half of 2026 demonstrated that our model can combine scientific innovation, entrepreneurial development and access to the capital markets. The listing of VERAXA marked another important milestone. The real test now lies in the clinical translation of the pipeline, securing additional strategic partners and delivering the next value drivers. At the same time, numerous other project companies achieved important operational progress. Our focus remains on creating sustainable value for our shareholders.*»

H1 2026 financial figures
In the first half of 2026 (as of June 30, 2026), Xlife Sciences generated revenue of CHF 476.234.- (prior-year period: CHF 354.321.-). Basic earnings per share amounted to CHF -29.08 (prior-year period: CHF -0.53). Total assets amounted to CHF 346.8 million (prior-year period: CHF 536.3 million). Equity amounted to CHF 206.3 million (prior-year period: CHF 391.9 million). Cash and cash equivalents amounted to CHF 595.485.- at the end of June 2026 (end of June 2025: CHF 51.553.-).

Outlook
For the second half of 2026, the focus is on continuing to support VERAXA in establishing industry partnerships, commercializing selected portfolio projects and expanding the Group's international network. At the same time, progress in diagnostics, biotechnology, digital medicine and technology platforms is to be advanced systematically into the next development phase. Xlife Sciences therefore considers itself well positioned to continue combining scientific innovation with entrepreneurial execution and access to the international capital markets.

The full Half-Year Report 2026 is available for download at the following link:
https://www.xlifesciences.ch/financials

Financial calendar

Annual Report 2026	April 28, 2027
Annual Shareholders Meeting 2027	June 25, 2027
Half-Year Report 2027	September 24, 2027

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (XLS SW)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch/

Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.